Berinert helps patients take control of their treatment with self-administration

Encourage your patients to treat at the first sign of attack
with Berinert on-demand therapy

Consider self-administration for all your Berinert patients. After proper training, patients may be able to recognize early symptoms and self-administer Berinert at the first sign of an HAE attack. On-demand treatment with Berinert via self-administration can offer HAE patients convenience and flexibility.

Berinert is approved for self-administration for acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adults and adolescents. Self-administration can be particularly important for life-threatening laryngeal HAE attacks. Advise patients to immediately seek medical attention if they have self-administered for a laryngeal attack.

Training and resources

Patients should be trained by a healthcare provider before attempting to self-administer Berinert. The BEN team can help arrange training for your patients through qualified specialty pharmacy providers, and can provide training materials as well. Here is a sampling of the support that Berinert provides to assist HAE patients with the self-administration process.

  • Contact B.E.N.™ or your patient’s specialty pharmacy to arrange training

    Call B.E.N.™ toll-free 24/7 at 1-877-BEN-4HAE (1-877-236-4423)

    To enroll with B.E.N.™, simply call the number above or download this form. Enrollment is open to all patients.

  • Review the detailed self-administration process step by step in this slideshow

  • Watch the instructional video

  • Patients can be prepared when they’re on the go! Visit Berinert.com on your mobile phone or use the QR code below to access these training resources on your smartphone. Bookmark the link to save a shortcut to your homescreen.

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Berinert for prophylactic therapy have not been established.

Berinert is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of Berinert and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Thrombotic events have been reported in patients receiving C1 esterase inhibitor products, including Berinert, at the recommended dose as well as when used off-label or at higher-than-labeled doses. Closely monitor patients with risk factors for thrombotic events.

Patients able to recognize signs and symptoms of HAE attack and comprehend necessary training can self-administer Berinert. Patients should not attempt to self-administer unless they have been trained and determined to be capable by healthcare provider. Advise patients to immediately seek medical attention following self-administration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of Berinert.

Berinert is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received Berinert in clinical studies was an increase in the severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

Berinert has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. The safety and efficacy of Berinert have not been established in children (ages 0 through 12) or in the geriatric population. In clinical trials, the half-life of Berinert was shorter and clearance was faster in children than in adults; the clinical implication is not known.

Please see full Prescribing Information.